COUR Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies designed ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a ...

Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the ...

点击蓝字关注我们神经性疼痛作为最顽固的慢性疼痛类型，在女性中的患病率显著高于男性。性别依赖的神经免疫机制是神经损伤引起的异常性疼痛的基础。动物实验表明小胶质细胞介导雄性慢性疼痛的发生过程，而适应性免疫系统介导雌性疼痛反应。Panx ...

The grant funding will further Tevogen Bio's mission to develop therapies for treatment of cancers and viral infections.Tevogen Bio may also utilize the grant funding to further expand its artificial ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.

Discover a clinical trial that was conducted to evaluate the efficacy and safety of autologous HBV vaccine-pulsed dendritic cells and their induced T cells.

编辑丨王多鱼排版丨水成文抗 PD-1 联合仑伐替尼（lenvatinib，一种多靶点受体酪氨酸激酶抑制剂）治疗在多种肿瘤中均显示出临床疗效，但潜在的免疫学机制尚不清楚。2025 年 1 月 30 ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HI ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of ...